Post-ERCP pancreatitis (PEP) is the most common serious adverse event attributed to the
procedure, resulting in annual estimated costs exceeding 150 million dollars in the United …

Endoscopic retrograde cholangiopancreatography (ERCP) carries a post-ERCP pancreatitis
(PEP) rate of 2–10%, which could be as high as 30–50% in high-risk cases. PEP is severe in …

Background Rectal indometacin decreases the occurrence of pancreatitis after endoscopic
retrograde cholangiopancreatography (ERCP). However, the population most at risk and the …

This review highlights advances made in recent years in the diagnosis and management of
acute pancreatitis (AP). We focus on epidemiological, clinical, and management aspects of …

Background and Aims Diclofenac and indomethacin are the most studied drugs for
preventing post-ERCP pancreatitis (PEP). However, there are no prospective, randomized …

Background and study aims Endoscopic retrograde cholangiopancreatography (ERCP) is
the primary therapeutic procedure for treatment of diseases that affect the biliary tree and …

Acute pancreatitis is currently the most common cause of hospital admission among all
nonmalignant gastrointestinal diseases. To understand the pathophysiology of the disease …

Pancreatitis is the most common and potentially devastating complication of endoscopic
retrograde cholangiopancreatography (ERCP), resulting in significant morbidity, occasional …

Background Although rectal indometacin 100 mg is effective in reducing the frequency and
severity of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in …

Pancreatitis is the most common adverse event of endoscopic retrograde
cholangiopancreatography, with the potential for clinically significant morbidity and mortality …